Overview

Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Firstline treatment for grade 13a Follicular Lymphoma using Opdivo (nivolumab) plus Rituximab: The 1st FLOR trial
Phase:
Phase 1
Details
Lead Sponsor:
Dr. Eliza Hawkes
Collaborator:
Bristol-Myers Squibb
Treatments:
Nivolumab
Rituximab